Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

36%

5 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

5(50.0%)

N/A

3(30.0%)

Phase 2

2(20.0%)

10Total

Phase 3(5)

N/A(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT06880250Enrolling By Invitation

Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease

Role: lead

NCT06568718Not ApplicableCompleted

Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Role: lead

NCT06834100Phase 3Recruiting

Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug

Role: lead

NCT06032442Not ApplicableCompleted

A Study to Assess Efficacy of Supporting Properties and Safety of ARTNEO in Patients With Knee Osteoarthritis

Role: lead

NCT06383819Phase 3Completed

Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

Role: lead

NCT03849560Phase 2Completed

Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers

Role: lead

NCT04381377Phase 2Completed

Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19

Role: lead

NCT05975879Not ApplicableCompleted

A Study of the Feasibility of Using the Dietary Supplement "ARTNEO" in Patients With Osteoathritis

Role: lead

NCT06385821Phase 3Completed

A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus

Role: lead

NCT04540419Phase 3Completed

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Role: lead

NCT04645368Completed

Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19

Role: lead

NCT04962620Unknown

Study of the Efficacy and Safety of Longidaze® for the Treatment of Patients With External Genital Endometriosis

Role: lead

NCT04542226Completed

Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19

Role: lead

NCT03840135Phase 3Completed

Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI

Role: lead

All 14 trials loaded